Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.
OBJECTIVE
This study evaluated the clinical significance of urinary CA19-9 levels in bladder cancer patients classified according to various combinations of Lewis (Le) and Secretor (Se) genotypes.


METHODS
Urinary CA19-9 and DU-PAN-2 levels were measured as units per mg creatinine (U/mg Cr) in 121 patients with bladder cancer and in 31 patients with other urologic diseases. Genotyping was carried out using polymerase chain reaction-based methods.


RESULTS
Urinary CA19-9-values in patients with both Le and Se alleles (Le/Le, Se/Se; Le/Le, Se/se; Le/le, Se/Se; Le/le, Se/se) were significantly higher (P < 0.0001) in bladder cancer cases compared to the other urologic diseases. The cut-off value determined using receiver operating characteristics analyses was 37.6 U/mg Cr. Approximately 70% (57/87) of bladder cancer patients with both Le and Se alleles demonstrated urinary CA19-9 levels over the cut-off value. In contrast, only 16% (4/24) of patients with other urologic diseases were over the cut-off value.


CONCLUSIONS
The urinary CA19-9 level can be a new effective diagnostic tool in bladder cancer patients with both Le and Se alleles.
Nagao
Keiji
K
Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. knagao@med.juntendo.ac.jp
Itoh
Yukio
Y
Fujita
Kazuhiko
K
Fujime
Makoto
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000951:Antigens, Neoplasm / Q000652:urine*; D018395:CA-19-9 Antigen / Q000652:urine*; D016022:Case-Control Studies; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000652:urine*
D000951:Antigens, Neoplasm; D018395:CA-19-9 Antigen; C042317:DU-PAN-2 antigen, human